Pharmaceutical Business review

AmerisourceBergen to sell Canadian pharmaceutical distribution business

The estimated sale price is expected to be between $80m and $100m, of which approximately half will be financed by AmerisourceBergen.

ABCC represents approximately 2% of AmerisourceBergen’s total revenues.

AmerisourceBergen, however, will retain its Canadian specialty business.

The transaction, which is subject to customary closing conditions, is likely to close in the third quarter of fiscal 2013.